These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 15827108

  • 1. Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation.
    Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, Kazama JJ, Fukagawa M, Noguchi S.
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4211-5. PubMed ID: 15827108
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T, Negi S, COLC Research Group.
    Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
    [Abstract] [Full Text] [Related]

  • 4. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
    Muras K, Masajtis-Zagajewska A, Nowicki M.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1901-8. PubMed ID: 24092829
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.
    Antoniucci DM, Yamashita T, Portale AA.
    J Clin Endocrinol Metab; 2006 Aug; 91(8):3144-9. PubMed ID: 16735491
    [Abstract] [Full Text] [Related]

  • 8. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
    Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y.
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
    Bogazzi F, Bartalena L, Campomori A, Brogioni S, Traino C, De Martino F, Rossi G, Lippi F, Pinchera A, Martino E.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
    [Abstract] [Full Text] [Related]

  • 11. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men.
    Burnett-Bowie SM, Mendoza N, Leder BZ.
    Bone; 2007 Apr; 40(4):913-8. PubMed ID: 17157573
    [Abstract] [Full Text] [Related]

  • 12. Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation.
    Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, Kazama JJ, Fukagawa M, Noguchi S.
    Endocr J; 2007 Jun; 54(3):465-70. PubMed ID: 17464094
    [Abstract] [Full Text] [Related]

  • 13. Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy.
    Kawamura S, Kishino B, Tajima K, Mashita K, Tarui S.
    J Clin Endocrinol Metab; 1983 Mar; 56(3):507-12. PubMed ID: 6185525
    [Abstract] [Full Text] [Related]

  • 14. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI, Maestro ML, Calvo N, De La Orden V, Pérez Flores I, Vidaurreta M, Valero R, Fernández-Pérez C, Barrientos A.
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [Abstract] [Full Text] [Related]

  • 15. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.
    Burnett SM, Gunawardene SC, Bringhurst FR, Jüppner H, Lee H, Finkelstein JS.
    J Bone Miner Res; 2006 Aug; 21(8):1187-96. PubMed ID: 16869716
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Fibroblast growth factor (FGF)-23 in patients with hypoparathyroidism].
    Yamashita H, Noguchi S, Yamasaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, Kazama J, Fukagawa M.
    Clin Calcium; 2005 Sep; 15 Suppl 1():41-5; discussion 45. PubMed ID: 16272628
    [Abstract] [Full Text] [Related]

  • 18. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.
    Ferrari SL, Bonjour JP, Rizzoli R.
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1519-24. PubMed ID: 15613425
    [Abstract] [Full Text] [Related]

  • 19. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
    Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Jüppner H, Wolf M.
    Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
    [Abstract] [Full Text] [Related]

  • 20. Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease.
    Mizuguchi Y, Morimoto S, Kimura S, Takano N, Yamashita K, Seki Y, Bokuda K, Yatabe M, Yatabe J, Watanabe D, Ando T, Ichihara A.
    PLoS One; 2018 Oct; 13(4):e0195464. PubMed ID: 29621332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.